• Abbott (NYSE: ABT) declared a quarterly common dividend of 55 cents per share.
• This marks the 403rd consecutive quarterly dividend to be paid by Abbott since 1924.
• The cash dividend is payable on Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024.
• Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500.
ABBOTT PARK, Ill., Sept. 19, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
This marks the 403rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024.
Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
| Last Trade: | US$112.64 |
| Daily Change: | 0.41 0.37 |
| Daily Volume: | 3,303,431 |
| Market Cap: | US$195.990B |
September 05, 2024 September 04, 2024 August 15, 2024 August 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
